Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Elotuzumab + Lenalidomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Elotuzumab||Empliciti||BMS-901608||Empliciti (elotuzumab) is a humanized monoclonal antibody against human CS1, which induces antibody-dependent cellular cytotoxicity in CS1-positive cells (PMID: 26005365). Empliciti (elotuzumab) is approved in combination with Revlimid (lenalidomide) and dexamethasone for use in patients with multiple myeloma (FDA.gov).|
|Lenalidomide||Revlimid||IMiD-1||Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03411031||Phase II||Elotuzumab + Lenalidomide Dexamethasone||Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide||Recruiting|
|NCT02279394||Phase II||Dexamethasone Elotuzumab + Lenalidomide||Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma||Active, not recruiting|
|NCT02420860||Phase II||Famotidine Elotuzumab + Lenalidomide Diphenhydramine Dexamethasone||Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT)||Recruiting|
|NCT02655458||Phase I||Elotuzumab + Lenalidomide||Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma||Completed|